At noon on July 23, Hisco announced that on July 23, the company made an inquiry through the official website of the State Drug Administration, and the State Drug Administration approved the listing of the Class 1 innovative drug siprocopan succinate tablets declared by the company. The indications approved for marketing this time are the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.

At noon on July 23, Hisco announced that on July 23, the company made an inquiry through the official website of the State Drug Administration, and the State Drug Administration approved the listing of the Class 1 innovative drug siprocopan succinate tablets declared by the company. The indications approved for marketing this time are the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.